Home>Topics>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries TEVA

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UPDATE 1- Teva Pharm sees 2015 revenue lower than forecast

      Headlines

      Thu, 11 Dec 2014

      TEL AVIV, Dec 11 (Reuters) - Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling...

    2. Teva Pharm sees lower than forecast 2015 revenue

      Headlines

      Thu, 11 Dec 2014

      TEL AVIV, Dec 11 (Reuters) - Teva Pharmaceutical Industries , the world's biggest generic drugmaker, forecast 2015 revenue below analysts' expectations and assumes its best-selling multiple sclerosis treatment will face competition in September.

    3. UPDATE 1-Court rules Hospira can launch generic Cubicin in 2016

      Headlines

      Mon, 8 Dec 2014

      (Adds information on earlier Teva settlement in paragraph 3)

    4. Teva Pharma names Peterburg new chairman

      Headlines

      Wed, 26 Nov 2014

      Nov 26 (Reuters) - The board of Teva Pharmaceutical Industries Ltd elected Yitzhak Peterburg as its chairman, succeeding Phillip Frost, who is due to step down at the end of the year.

    5. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

      Headlines

      Tue, 4 Nov 2014

      have posted solid gains in this year's challenging conditions, including top-25 holdings Shire SHP, Teva Pharmaceutical Industries TEVA , Taiwan Semiconductor Manufacturing TSM, Baidu BIDU, and Avago Technologies AVGO. As a result, this

    6. Teva's Cost-Reduction Efforts Bolster Third-Quarter Bottom-Line Results

      Commentary

      Thu, 30 Oct 2014

      Although Teva ’s flat revenue growth during the third quarter ..... Despite weak growth trends in most of Teva ’s segments, the company’s cost reduction ..... performance over the coming quarters. Meanwhile, Teva ’s specialty drug segment posted stable

    7. Teva Review Raises Concerns and Mesoblast Marks Time; Fair Value Unchanged

      Commentary

      Thu, 16 Oct 2014

      Mesoblast partner Teva Pharmaceuticals has announced it will discontinue ..... failure, or CHF, partnered with Mesoblast. Teva expects to realise cost savings of approximately ..... period which will be redirected towards Teva 's core therapeutic areas of central nervous

    8. A Testing Time for Mesoblast, Potential Clinical Catalysts Still Months Away

      Commentary

      Tue, 26 Aug 2014

      patient phase III trial in congestive hear failure partnered with TEVA is the most important of these being pursued with the MPC platform ..... valuation. Patient recruitment in the phase III trial partnered with TEVA is ongoing with interim results expected in 2015. Notably

    9. Appleseed Letter to Shareholders

      Headlines

      Tue, 12 Aug 2014

      PAGEBREAK> At the current time, the Appleseed Fund’s equity portfolio owns healthcare stocks such as Teva Pharmaceuticals ( TEVA ), Novartis (NVS), and PDI Inc. (PDII) due in part to our view that healthcare will continue to grow faster

    10. Mylan Will Likely Need Key Product Approvals to Meet Uncertain Year-End Outlook

      Commentary

      Thu, 7 Aug 2014

      outlook of $3.25 to $3.45 due to our estimate of an ongoing delay in key product launches, particularly a generic version of Teva ’s Copaxone. We have made no major changes to our longer-term forecast, including the integration of Abbott’s non

    « Prev12345Next »
    Content Partners